Clinical trials: Cancer Disease Progression
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Gastric Carcinoma, Gastritis Chronic
Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis
The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk…
- Conditions
- Gastric Carcinoma, Gastritis Chronic, Intestinal Metaplasia, Gastric Precancerous Lesions
- Trial name
- NCT07542652
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Yongquan Shi
NeuroEndocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in…
- Trial name
- CALM-NET (NCT02075606)
- Testing
- lanreotide acetate
- Where
- 14 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Ipsen
Glioblastoma
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line [2L] treatment) and SOC (in 3rd-line [3L] and…
- Trial name
- NCT01860638
- Testing
- Bevacizumab, Lomustine, Radiotherapy
- Where
- 64 sites in Austria, Bulgaria and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Metastatic Clear Cell Renal Cell Carcinoma
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy.
- Trial name
- RENALUT (NCT06783348)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head & Neck Cancer
Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma
This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of vibecotamab combined with putelimab in the treatment of locally advanced laryngeal carcinoma.
- Trial name
- NCT07538206
- Testing
- Vibecotamab Injection
- Volunteers
- 10 people
- Sponsor
- Tang-Du Hospital
Brain Metastases
ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment.
- Trial name
- GK-ASL (NCT04833335)
- Testing
- MRI perfusion sequence
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cervical Cancer
p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management
The objective of this study is to evaluate the outcome of cervical intraepithelial neoplasia grade 2 (CIN-II) patients followed up without treatment for 24 months according to p16 and ki-67 immunohistochemical staining and to the…
- Trial name
- NCT02522585
- Testing
- Conservative management
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
This is a large non-interventional observational bidirectional study planned to collect clinically relevant data and prognostic follow-up information of patients with cervical cancer who were seen at our center from 2010.01.01 to…
- Trial name
- NCT06480617
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Anhui Provincial Hospital
Colorectal Cancer, Colorectal Adenocarcinoma
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
The goal of this clinical research study is to learn if adding brivanib to irinotecan can help control the disease in patients with colorectal cancer that has spread. The safety of this drug combination will also be studied.
- Trial name
- NCT01367275
- Testing
- Brivanib, Irinotecan
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer is typically diagnosed at an advanced stage and remains associated with poor long-term survival. Reliable biomarkers for predicting disease course and treatment response are still limited.
- Trial name
- NCT07439328
- Testing
- Peripheral Blood Collection for CTC Isolation and Analysis
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Castrate-resistant Metastatic Prostate Cancer
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Cabazitaxel is already approved by the Food and Drug Administration (FDA) for use in patients with advanced prostrate cancer, following docetaxel therapy.
- Trial name
- NCT01750866
- Testing
- Cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF)
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Multiple Myeloma in Relapse
CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression
- Trial name
- NCT03672253
- Testing
- CAR-T Re-treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Bladder Cancer, Disease Progression
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive…
- Conditions
- Bladder Cancer, Disease Progression, Recurrent Bladder Cancer
- Trial name
- NCT03174912
- Testing
- Intravesical BCG instillation
- Volunteers
- 400 people
- Sponsor
- Ankara Training and Research Hospital
Skin Cancer, Diagnostic
Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions
Actinic keratoses are precancerous skin lesions that are the most common among all cancers and precancerous conditions in fair-skinned populations.
- Trial name
- DIAGNO-KA (NCT07624981)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Non Small Cell Lung Cancer, Small-cell Lung Cancer
DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
- Trial name
- REGISTURK-LUNG (NCT05254119)
- Where
- 39 sites in Turkey (Türkiye)
- Volunteers
- 6,000 people
- Sponsor
- Mahmut Gumus
Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Chemoimmunotherapy, Complete Pathological Response
- Trial name
- NCT05925751
- Testing
- CT/PET/WSI-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Esophageal Squamous Cell Carcinoma (ESCC)
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor…
- Trial name
- NCT06746961
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib
- Volunteers
- 49 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Bladder Cancer
Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates
Purpose To investigate the significance of time to re-staging transurethral resection (re-TUR) on recurrence and progression rates in patient with high-risk non-muscle-invasive bladder cancer.
- Trial name
- NCT04768894
- Testing
- Second transurehral resection of bladder tumour
- Volunteers
- 109 people
- Sponsor
- Saglik Bilimleri Universitesi
Limited-stage Small Cell Lung Cancer, LS-SCLC
A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer
SHR-1316 as Maintenance therapy for limited stage small cell lung cancer without progression after first line platinum based concurrent chemoradiotherapy
- Trial name
- NCT04647357
- Testing
- SHR-1316
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.